Journal article
A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy
EJ Aspinall, W Mitchell, J Schofield, A Cairns, S Lamond, P Bramley, SE Peters, H Valerio, J Tomnay, DJ Goldberg, PR Mills, ST Barclay, A Fraser, JF Dillon, NK Martin, M Hickman, SJ Hutchinson
Journal of Viral Hepatitis | WILEY-BLACKWELL | Published : 2016
DOI: 10.1111/jvh.12580
Abstract
Prisoners are a priority group for hepatitis C (HCV) treatment. Although treatment durations will become shorter using directly acting antivirals (DAAs), nearly half of prison sentences in Scotland are too short to allow completion of DAA therapy prior to release. The purpose of this study was to compare treatment outcomes between prison- and community-based patients and to examine the impact of prison release or transfer during therapy. A national database was used to compare treatment outcomes between prison treatment initiates and a matched community sample. Additional data were collected to investigate the impact of release or transfer on treatment outcomes. Treatment-naïve patients infe..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
MH acknowledges support from the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at University of Bristol. NM acknowledges support from the National Institute for Drug Abuse [grant number R01 DA037773-01A1] and University of California San Diego Center for AIDS Research (CFAR), a National Institute of Health (NIH) funded program [grant number P30 AI036214]. The views expressed are those of the authors, and not necessarily those of the UK NHS, the UK NIHR or the UK Department of Health. The authors would like to acknowledge the Clinical Database Monitoring Committee, the Clinical Database data entry staff at the participating NHS Health Boards, and the Scottish Government for funding the Scottish Clinical Database. JD has received honoraria for lectures, advisory panels and support to attend conferences from Janssen, Roche, MSD, Gilead, BMS and Boeringer Ingelheim, and his institution has received grants for research from Janssen, Roche, MSD, Gilead and BMS. SL has been on the nurse advisory board for Abbvie and BMS. DJG has received honoraria for educational contributions (e.g. lectures, reports) and for providing advice on aspects of hepatitis C and public health from Abbvie, Merck, Gilead, BMS, and Janssen. MH has received unrestricted research grants as co-investigator from Gilead and honoraria from Gilead and Janssen. NM has received unrestricted research grants from Gilead unrelated to this work and honoraria from Merck, AbbVie and Janssen. All other authors declare that they have no conflicts of interest in relation to this manuscript.